Susan S Jick1, Katrina W Hagberg, Rohini K Hernandez, James A Kaye. 1. Boston Collaborative Drug Surveillance Program, Department of Epidemiology, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA. sjick@bu.edu
Abstract
BACKGROUND: Concern has been raised that the risk of venous thromboembolism (VTE) in users of the ORTHO EVRA patch is higher compared to users of oral contraceptives (OCs). STUDY DESIGN: We identified idiopathic cases of VTE and controls, matched on age and index date, from among women in the United States PharMetrics/IMS and MarketScan databases who were current users of the patch or levonorgestrel-containing OCs with 30 mcg of ethinyl estradiol. We calculated odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The ORs (95% CI) for VTE in users of the patch compared to levonorgestrel-containing OCs were 2.0 (0.9-4.1) and 1.3 (0.8-2.1) in the PharMetrics and MarketScan databases, respectively. ORs (95% CI) restricted to women aged 39 years or younger were 1.4 (0.6-3.0) and 1.2 (0.7-2.0), respectively. CONCLUSION: These results provide evidence that the risk of idiopathic VTE in users of the patch is not materially different than that of users of levonorgestrel-containing OCs in women aged 39 years or younger. We cannot rule out some increase in the risk in women aged 40 years or older.
BACKGROUND: Concern has been raised that the risk of venous thromboembolism (VTE) in users of the ORTHO EVRA patch is higher compared to users of oral contraceptives (OCs). STUDY DESIGN: We identified idiopathic cases of VTE and controls, matched on age and index date, from among women in the United States PharMetrics/IMS and MarketScan databases who were current users of the patch or levonorgestrel-containing OCs with 30 mcg of ethinyl estradiol. We calculated odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The ORs (95% CI) for VTE in users of the patch compared to levonorgestrel-containing OCs were 2.0 (0.9-4.1) and 1.3 (0.8-2.1) in the PharMetrics and MarketScan databases, respectively. ORs (95% CI) restricted to women aged 39 years or younger were 1.4 (0.6-3.0) and 1.2 (0.7-2.0), respectively. CONCLUSION: These results provide evidence that the risk of idiopathic VTE in users of the patch is not materially different than that of users of levonorgestrel-containing OCs in women aged 39 years or younger. We cannot rule out some increase in the risk in women aged 40 years or older.
Authors: Cameron C Trenor; Richard J Chung; Alan D Michelson; Ellis J Neufeld; Catherine M Gordon; Marc R Laufer; S Jean Emans Journal: Pediatrics Date: 2011-01-03 Impact factor: 7.124
Authors: Mary A Vogler; Kristine Patterson; Lori Kamemoto; Jeong-Gun Park; Heather Watts; Francesca Aweeka; Karin L Klingman; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2010-12 Impact factor: 3.731
Authors: A J Jakimiuk; P G Crosignani; T Chernev; V Prilepskaya; P Bergmans; M Von Poncet; S Marelli; E J Lee Journal: Gynecol Endocrinol Date: 2010-12-10 Impact factor: 2.260
Authors: Robert A Christian; Sarah T Lander; Nicholas A Bonazza; Emily K Reinke; Trevor A Lentz; Julie A Dodds; Mary K Mulcahey; Anne C Ford; Jocelyn R Wittstein Journal: Arthrosc Sports Med Rehabil Date: 2022-01-26